Company Overview
Enveric Biosciences, Inc. operates as a biotechnology company focused on the development of small-molecule therapeutics designed to treat anxiety, depression, and addiction disorders. The company's primary product candidate, EB-002, is an active metabolite of psilocybin and is currently in preclinical development stages. Enveric functions within the Healthcare sector, specifically under the Biotechnology industry, which implies a reliance on high-risk, high-reward research and development cycles before potential commercialization. The company currently maintains a market capitalization of $2.61M and employs 5 individuals to support its operational and research activities. These valuation and workforce metrics indicate that Enveric is an early-stage micro-cap entity with a minimal operational footprint, suggesting that its current revenue generation capabilities are likely negligible given its primary focus on preclinical assets rather than established commercial sales.
Financial Health
Enveric Biosciences, Inc. reports a Net Income of $-11,245,911 and an EBITDA of $-9,510,491 for the trailing twelve months, while Revenue figures are listed as N/A. The substantial gap between the reported Net Income and the less negative EBITDA reveals a significant cost structure driven by non-operating expenses, likely related to interest or other financing costs, rather than core operational inefficiencies. The company generates Free Cash Flow of $-3,897,664, which indicates a negative cash position where outflows for operations and investments exceed cash inflows, necessitating external capital raising to sustain operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the fact that the company has not yet achieved positive profitability or generated measurable revenue to calculate traditional margin percentages. On the balance sheet, the company holds Cash of $3.76M with Debt listed as N/A, resulting in a Debt to Equity ratio of N/A, which suggests a conservative capital structure free of traditional interest-bearing liabilities at this stage. The Current Ratio stands at 4.60, indicating that the company possesses ample short-term assets relative to its short-term obligations, thereby demonstrating strong short-term liquidity despite the lack of revenue. Return on Equity is -262.8% and Return on Assets is -133.2%, metrics that reveal significant value destruction in the current period due to heavy losses relative to the company's equity and asset base, highlighting the challenges of sustaining growth without positive earnings.
Valuation Assessment
The trailing P/E Ratio (TTM) is 0.00 and the Forward P/E is -1.33, a disparity that implies the market cannot value the company based on current earnings since they are negative, while the forward metric suggests an expectation of continued losses or a specific accounting treatment for future earnings estimates. The Price to Book ratio is 0.28, indicating that the stock trades at a significant discount to its book value, which often reflects the market's skepticism regarding the recoverability of assets in a preclinical biotechnology context. Price to Sales is N/A and the EV/EBITDA is 0.28, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable, though the low EV/EBITDA figure relative to the high negative earnings might reflect the specific calculation methodology used for entities with no revenue or minimal EBITDA. The 52-Week High is $21.24 and the 52-Week Low is $1.82, providing a trading range of approximately 19.42 points, though the specific current price location within this range cannot be precisely calculated without the real-time share price. The Beta is 0.30, which indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the overall index during periods of market fluctuation.
Growth & Income
Revenue Growth (YoY) is N/A and Earnings Growth (YoY) is N/A, preventing any quantitative assessment of whether earnings are growing faster or slower than revenue since neither metric has a positive base to measure against. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute cash to shareholders, implying that the organization reinvests all available resources, including its $3.76M cash reserve, directly into research and development efforts rather than paying dividends. The overall growth and income profile is characterized by a complete absence of historical growth rates and dividend income, typical for early-stage biotechnology firms that prioritize asset development over shareholder distributions. This profile necessitates a reliance on equity financing to fund operations, as the company cannot generate internal cash flow or income streams sufficient to support independent growth without external investment.